Log In
Print
BCIQ
Print
Print this Print this
 

muparfostat (PI-88)

  Manage Alerts
Collapse Summary General Information
Company Progen Pharmaceuticals Ltd.
DescriptionSulfated mannopentaose phosphate anti-angiogenic agent that inhibits VEGF, FGF and heparanase activity
Molecular Target Vascular endothelial growth factor (VEGF) ; Fibroblast growth factor (FGF)
Mechanism of ActionAngiogenesis inhibitor; Vascular endothelial growth factor (VEGF) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationLiver cancer
Indication DetailsAdjuvant treatment of hepatitis virus-related hepatocellular carcinoma (HCC) after surgical resection; Treat hepatocellular carcinoma (HCC) following primary tumor resection; Treat primary liver cancer
Regulatory Designation

U.S. - Orphan Drug (Adjuvant treatment of hepatitis virus-related hepatocellular carcinoma (HCC) after surgical resection);
EU - Orphan Drug (Adjuvant treatment of hepatitis virus-related hepatocellular carcinoma (HCC) after surgical resection)

Partner

Medigen Biotechnology Corp.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today